The actual incidence rate of mild cognitive impairment(MCI)is relatively high,and it has a significant impact on people's well-being,but its discovery is relatively difficult,which poses a new challenge for early diagnosis treatment and the monitoring of the course of the disease.Biomarkers for MCI could provide timely assistance in its diag-nosis and treatment.Recently,metabolomics technology has demonstrated promising results in identifying biomarkers for MCI.Therefore we review the key findings of metabolomics in MCI research,including the identification of crucial me-tabolites,abnormalities in metabolic pathways and their association with the pathophysiological processes of MCI.The application of metabolomics technology could provide new insights and important theoretical foundations for the develop-ment of the early diagnosis,precision medicine,and personalized treatment strategies of MCI.
NETL
NSTL
万方数据
